MediSapiens to Provide Bioinformatics Application to Bayer HealthCare

MediSapiens to Provide Bioinformatics Application to Bayer HealthCare

HELSINKI, May 13, 2014 /PRNewswire/ --

MediSapiens Ltd, a Finnish company developing bioinformatics applications for the pharmaceutical industry, today announced that it will provide Bayer HealthCare with a new software solution for analysis and visualization of genomics data. This software system, called the Integrated Genomics Platform, will serve as a centralized access to genomics data used throughout a research organization. The Integrated Genomics Platform provides storage and access to a vast collection of clinical genomics data, coupled with an extensive set of tools for analysis and visualization of the data.

"Data alone serves very little purpose. Without structure and proper means of interpretation, it is merely numbers. And when we talk about genomics data, the sheer amount of it is almost terrifying. The Integrated Genomics Platform will turn the vast pool of genomics data into knowledge that can be used to drive decision-making processes in pharmaceutical research and development," says Sami Kilpinen, CEO of MediSapiens.

About MediSapiens

MediSapiens is a bioinformatics company developing inspiring web applications for genomics researchers, the pharmaceutical industry and personalized medicine. MediSapiens has unique know-how in developing software solutions for integration of both molecular and clinical data from preclinical models to interpreting comprehensive molecular profiles of individual cancer patients in clinical settings. Based on the world's largest unified gene expression database, MediSapiens' platform extends into highly tailored solutions to meet the exact needs of various demanding research environments.

For more information visit or email [email protected]

Media Contact:
Sami Kilpinen, CEO, Co-Founder
MediSapiens Ltd
Erottajankatu 19B
00130 Helsinki
[email protected]


BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.